** Shares of drug developer Passage Bio PASG.O fall 12% to 38 cents premarket
** Co says it is doing a 1-for-20 reverse stock split, effective July 14, 2025
** For every 20 shares, shareholders will now have 1 share, co says
** The number of outstanding shares will drop from about 62.4 million to about 3.1 million and the stock will keep trading under the symbol 'PASG', Passage Bio says
** PASG is currently developing gene therapies for rare, inherited neurodegenerative diseases, The company's programs focus mainly on treating disorders that affect the central nervous system
** As of last close, PASG stock down 22.2% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.